ABAndrew Brodbelt

Andrew Brodbelt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Brodbelt has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adult glioblastoma in England: Incidence, treatment, and outcomes with novel population-based strata

    by Kerlann Le Calvez, Radvile Mauricaite, Peter Treasure, Thomas C. Booth, Stephen J. Price, Andrew Brodbelt, Jonathan J. Gregory, Seema Dadhania, Lillie Pakzad-Shahabi, Maureen Dumba, et al.


  • Open Access

    IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

    by Georgette Tanner, Rhiannon Barrow, Shoaib Ajaib, Muna Al-Jabri, Nazia Ahmed, Steven Pollock, Martina Finetti, Nora Rippaus, Alexander F. Bruns, Khaja Syed, et al.

    Background: Glioblastoma (GBM) brain tumors lackingIDH1mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.Results: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.Conclusions: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.


  • Open Access

    QUANTIFYING THE NEED FOR A BEST SUPPORTIVE CARE CLINIC

    by Marwan Al-Munaer, Sam Holman, Emma Wilby, Andrew Brodbelt

    Patients newly diagnosed with high-grade primary brain tumour and poor performance status discussed in the Multidisciplinary team (MDT) may not be felt to benefit from active treatment and their uptake in clinic is poor. We aimed to explore the volume of patients not being treated in our region, their survival rates, and the reasons for the limited requests for clinical review. Data was obtained from medical records of identified patients from April 2021 to April 2022. This included demographics, presentation, diagnosis date, clinic visits, and date of death. 78 patients were referred for suspected high-grade primary brain tumours and selected for best supportive care by the MDT. Only 73 (64% male) were diagnosed radiologically with a high-grade primary tumour and the rest were excluded. Median age was 79 years (range 74 – 84). The commonest presenting symptoms were confusion (53%), falls (29%), and dysphasia (25%). Median survival time after diagnostic scan was 67 days (range 34 – 107). Survival rates at 1, 3, 6, and 12 months were 82%, 33%, 8%, and 1%, respectively. 28 patients (38%) were seen in clinic. 13 had been provided with the option to attend by letter. The median duration from referral to clinic was 9 days (range 7 – 14). Only a third of non-treatable patients with newly diagnosed high-grade primary brain tumours are being seen in the clinic. Communication between the MDT and the patient offering this service is poor. Longer term survivors suggest an incorrect diagnosis who may benefit from further review.

  • Open Access

    Correction to: Cranial meningioma with bone involvement: surgical strategies and clinical considerations

    by Abigail L. Clynch, Max Norrington, Mohammad A. Mustafa, George E. Richardson, John A. Doherty, Thomas J. Humphries, Conor S. Gillespie, Sumirat M. Keshwara, Catherine J. McMahon, Abdurrahman I. Islim, et al.


  • Open Access

    Health-related quality of life following cranioplasty – a systematic review

    by Mohammad A. Mustafa, George E. Richardson, Conor S. Gillespie, Abigail L. Clynch, Sumirat M. Keshwara, Shubhi Gupta, Alan M. George, Abdurrahman I. Islim, Andrew R. Brodbelt, Christian Duncan, et al.

    Cranioplasty is a neurosurgical procedure that repairs a defect in the skull Coupled with the underlying pathology cranioplasty associated morbidity can have a large impact on patient quality of life, which is often poorly explored. The objective of this systematic review was to identify patient-reported outcomes evaluating health-related quality of life following cranioplasty. The review protocol was registered on PROSPERO (CRD42021251543) and a systematic review was conducted in accordance with the PRISMA statement. PubMed, Embase, CINAHL Plus, and the Cochrane databases were searched from inception to 1 May 2022. All studies reporting HRQoL following cranioplasty were included. Reporting was assessed using the ISOQOL checklist and risk of bias was assessed using the Newcastle-Ottawa Scale or the Johanna-Briggs Institute Scale, as appropriate. A total of 25 studies were included of which 20 were cross-sectional and 2 longitudinal. Most studies utilized study specific questionnaires and Likert scales to assess HRQoL. The studies found a significant improvement in physical functioning, social functioning, cosmetic outcome, and overall HRQoL following cranioplasty. Further longitudinal studies utilising validated measurement tools are required to better understand the effect of cranioplasty at a patient level.


  • Open Access

    Cranial meningioma with bone involvement: surgical strategies and clinical considerations

    by Abigail L. Clynch, Max Norrington, Mohammad A. Mustafa, George E. Richardson, John A. Doherty, Thomas J. Humphries, Conor S. Gillespie, Sumirat M. Keshwara, Catherine J. McMahon, Abdurrahman I. Islim, et al.

    Background: Intracranial meningioma with bone involvement and primary intraosseous meningioma is uncommon. There is currently no consensus for optimal management. This study aimed to describe the management strategy and outcomes for a 10-year illustrative cohort, and propose an algorithm to aid clinicians in selecting cranioplasty material in such patients. Methods: A single-centre, retrospective cohort study (January 2010–August 2021). All adult patients requiring cranial reconstruction due to meningioma with bone involvement or primary intraosseous meningioma were included. Baseline patient and meningioma characteristics, surgical strategy, and surgical morbidity were examined. Descriptive statistics were performed using SPSS v24.0. Data visualisation was performed using R v4.1.0. Results: Thirty-three patients were identified (mean age 56 years; SD 15) There were 19 females. Twenty-nine patients had secondary bone involvement (88%). Four had primary intraosseous meningioma (12%). Nineteen had gross total resection (GTR; 58%). Thirty had primary ‘on-table’ cranioplasty (91%). Cranioplasty materials included pre-fabricated polymethyl methacrylate (pPMMA) (n = 12; 36%), titanium mesh (n = 10; 30%), hand-moulded polymethyl methacrylate cement (hPMMA) (n = 4; 12%), pre-fabricated titanium plate (n = 4; 12%), hydroxyapatite (n = 2; 6%), and a single case combining titanium mesh with hPMMA cement (n = 1; 3%). Five patients required reoperation for a postoperative complication (15%). Conclusion: Meningioma with bone involvement and primary intraosseous meningioma often requires cranial reconstruction, but this may not be evident prior to surgical resection. Our experience demonstrates that a wide variety of materials have been used successfully, but that pre-fabricated materials may be associated with fewer postoperative complications. Further research within this population is warranted to identify the most appropriate operative strategy.


  • Open Access

    Cranioplasty with hydroxyapatite or acrylic is associated with a reduced risk of all-cause and infection-associated explantation

    by Christopher P. Millward, John A. Doherty, Mohammad A. Mustafa, Thomas J. Humphries, Abdurrahman I. Islim, George E. Richardson, Abigail L. Clynch, Conor S. Gillespie, Sumirat M. Keshwara, Ruwanthi Kolamunnage-Dona, et al.

    Cranioplasty remains an essential procedure following craniectomy but is associated with high morbidity. We investigated factors associated with outcomes following first alloplastic cranioplasty.A ...


  • Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?

    by Farouk Olubajo, Antonia Thorpe, Charles Davis, Rohitashwa Sinha, Anna Crofton, Samantha J. Mills, Matthew Williams, Michael D. Jenkinson, Stephen J. Price, Colin Watts, et al.

    Tumour Treating Fields (TTF) in combination with standard therapy, prolongs survival in patients with glioblastoma (GBM). The aim of the current study was to assess the feasibility of integrating T...


  • A retrospective review of the clinical outcomes of lung cancer patients referred into the Regional Neuro-Oncology Pathway in 2020 in Merseyside, United Kingdom

    by Jonathan Heseltine, Ana Corte, Oliver Kennedy, Harry Sharples, Helen Wong, Andrew Brodbelt, Shaveta Mehta

  • A retrospective review of the management of lung cancer patients referred into the regional neuro-oncology pathway in Merseyside, United Kingdom

    by Jonathan Heseltine, Ana Corte, Oliver Kennedy, Harry Sharples, Helen Wong, Andrew Brodbelt, Shaveta Mehta